Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kezar Life Sciences, Inc. filings document a clinical-stage biotechnology issuer through material-event reports, capital-structure disclosures, governance matters and corporate-status records. The company’s 8-K filings cover zetomipzomib program updates, operating and financial results, amendments affecting preferred share purchase rights, repayment and termination of a loan agreement, and restructuring costs associated with exit activities.
The filing record also documents completed transaction and status events, including the asset purchase agreement transferring Kezar’s Sec61-based discovery and development program assets, including KZR-261, to Enodia Therapeutics, tender-offer consideration involving cash and contingent value rights, and Nasdaq’s Form 25 notice for removal of Kezar common stock from listing and registration.
Kezar Life Sciences director John Franklin Fowler received a stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation grant. The vesting schedule indicates a one-year cliff vesting period, which aligns with typical board member equity compensation structures. The 10-year exercise window from grant date is also standard practice for director stock options.
Kezar Life Sciences (Nasdaq: KZR) filed a Form 8-K disclosing the voting results of its 17 June 2025 annual meeting (Item 5.07).
Shareholders elected three Class I directors to serve until the 2028 meeting: Elizabeth Garner, M.D. (2,148,505 for / 1,793,162 withheld), Michael Kauffman, M.D., Ph.D. (1,618,735 for / 2,322,932 withheld) and Courtney Wallace (1,551,353 for / 2,390,314 withheld).
The meeting also approved, on an advisory basis, executive compensation (2,151,745 for; 1,781,942 against; 7,980 abstain) and ratified KPMG LLP as independent auditor for fiscal 2025 (6,116,820 for; 56,801 against; 8,526 abstain).
No financial performance updates, strategic announcements or other material events were included.